Literature DB >> 22164189

Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America.

Adriana Carrá, Miguel Ángel Macías-Islas, Alberto Alan Gabbai, Jorge Correale, Carlos Bolaña, Eduardo Duriez Sotelo, Juan García Bonitto, Fernando Vergara-Edwards, Darwin Vizcarra-Escobar.   

Abstract

OBJECTIVE: The prevalence of multiple sclerosis (MS) in Latin America varies across different studies but an intermediate risk and increased frequency of the disease have been reported in recent years. The circumstances of Latin American countries are different from those of Europe and North America, both in terms of differential diagnoses and disease management.
METHODS: An online survey on MS was sent to 855 neurologists in nine Latin American countries. A panel of nine experts in MS analyzed the results.
RESULTS: Diagnostic and therapeutic recommendations were outlined with special emphasis on the specific needs and circumstances of Latin America. The experts proposed guidelines for MS diagnosis, treatment, and follow up, highlighting the importance of considering endemic infectious diseases in the differential diagnoses of MS, the identification of patients at high risk of developing MS in order to maximize therapeutic opportunities, early treatment initiation, and cost-effective control of treatment efficacy, as well as global assessment of disability.
CONCLUSIONS: The experts recommended that healthcare systems allocate a longer consultation time for patients with MS, which must be conducted by neurologists trained in the management of the disease. All drugs currently approved must be available in all Latin American countries and must be covered by healthcare plans. The expert panel supported the creation of a permanent forum to discuss future clinical and therapeutic recommendations that may be useful in Latin American countries.

Entities:  

Keywords:  glatiramer acetate; immunomodulators; interferon-beta; mitoxantrone; multiple sclerosis; natalizumab

Year:  2011        PMID: 22164189      PMCID: PMC3229255          DOI: 10.1177/1756285611423560

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  52 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

Review 2.  A systematic review of the epidemiology of multiple sclerosis in South America.

Authors:  E Cristiano; L Patrucco; J I Rojas
Journal:  Eur J Neurol       Date:  2008-12       Impact factor: 6.089

3.  Prevalence of multiple sclerosis in Buenos Aires, Argentina using the capture-recapture method.

Authors:  E Cristiano; L Patrucco; J I Rojas; F Cáceres; A Carrá; J Correale; O Garcea; L Gold; J Tessler; M Kremenchutzky
Journal:  Eur J Neurol       Date:  2008-12-09       Impact factor: 6.089

Review 4.  Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies.

Authors:  Tracy DeAngelis; Fred Lublin
Journal:  Mt Sinai J Med       Date:  2008 Mar-Apr

5.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

Authors:  M Tintoré; A Rovira; J Río; C Tur; R Pelayo; C Nos; N Téllez; H Perkal; M Comabella; J Sastre-Garriga; X Montalban
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

6.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

Review 7.  Treatment optimization in multiple sclerosis: report of an international consensus meeting.

Authors: 
Journal:  Eur J Neurol       Date:  2004-01       Impact factor: 6.089

8.  Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.

Authors:  D S Goodin; B Hurwitz; A Noronha
Journal:  J Int Med Res       Date:  2007 Mar-Apr       Impact factor: 1.671

9.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  7 in total

1.  Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis.

Authors:  Maria Carolina de Oliveira Rodrigues; Nelson Hamerschlak; Daniela Aparecida de Moraes; Belinda Pinto Simões; Morgani Rodrigues; Andreza Alice Feitosa Ribeiro; Júlio César Voltarelli
Journal:  Rev Bras Hematol Hemoter       Date:  2013

2.  Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.

Authors:  Mathias Buttmann; Linda Seuffert; Uwe Mäder; Klaus V Toyka
Journal:  Neurology       Date:  2016-05-11       Impact factor: 9.910

Review 3.  Access and barriers to MS care in Latin America.

Authors:  Víctor M Rivera; Miguel Angel Macias
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-03-23

4.  Mediational Model of Multiple Sclerosis Impairments, Family Needs, and Caregiver Mental Health in Guadalajara, Mexico.

Authors:  Melody N Mickens; Paul B Perrin; Adriana Aguayo; Brenda Rabago; Miguel A Macías-Islas; Juan Carlos Arango-Lasprilla
Journal:  Behav Neurol       Date:  2018-01-17       Impact factor: 3.342

5.  Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats.

Authors:  Mohamed A El-Emam; Samar El Achy; Dalaal M Abdallah; Hanan S El-Abhar; Mennatallah A Gowayed
Journal:  BMC Neurosci       Date:  2022-03-05       Impact factor: 3.288

6.  Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate.

Authors:  Tjalf Ziemssen; Yossi Gilgun-Sherki
Journal:  BMC Neurol       Date:  2015-10-08       Impact factor: 2.474

Review 7.  Application of the McDonald criteria in Latin America.

Authors:  Liliana Patrucco
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.